OncoMatch/Clinical Trials/NCT06601309
Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC
Is NCT06601309 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Serplulimab and Paclitaxel+Cisplatin (Neoadjuvant Chemotherapy) for esophageal squamous cell carcinoma.
Treatment: Serplulimab · Paclitaxel+Cisplatin (Neoadjuvant Chemotherapy) · Paclitaxel+Cisplatin(Concurrent Chemoradiotherapy) — This study aims to evaluate the impact of the neoadjuvant treatment strategy based on CPS score on the pathological complete response (pCR) rate in patients with resectable locally advanced esophageal cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) expression (CPS) available (available)
Available PD-L1 expression level (CPS)
Disease stage
Required: Stage II, III
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-PD-1 therapy
Previous treatment with anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibodies
Cannot have received: anti-PD-L1 therapy
Previous treatment with anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibodies
Cannot have received: anti-CTLA-4 therapy
Previous treatment with anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibodies
Lab requirements
Blood counts
absolute neutrophil count (anc) ≥ 1.5 x 10^9/l, platelets ≥ 100 x 10^9/l, hemoglobin ≥ 9 g/dl
Kidney function
serum creatinine ≤ 1.5 x uln or creatinine clearance ≥ 60 ml/min
Liver function
total bilirubin ≤ 1.5 x uln, ast and alt ≤ 2.5 x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify